|
Published by: Kalorama Information
Published: Oct. 1, 1996 - 247 Pages Now 50% off the original sale price of $3,250.
Table of Contents
Chapter One: Executive Summary
Genitourinary Diseases and Disorders
Benign Prostatic Hyperplasia
Incidence and Prevalence of Benign Prostatic Hyperplasia
Treatment for Benign Prostatic Hyperplasia
Genitourinary Cancers
Incidence and Prevalence of Genitourinary Cancers
Treatment of Bladder Cancer
Treatment of Cervical Cancer
Treatment of Kidney/Renal Cancer
Treatment of Ovarian Cancer
Treatment of Prostate Cancer
Erectile Dysfunction
Incidence and Prevalence of Erectile Dysfunction
Treatment of Erectile Dysfunction
Incontinence
Incidence and Prevalence of Incontinence
Treatment of Incontinence
Sexually Transmitted Diseases
Incidence and Prevalence of Sexually Transmitted Diseases
Treatment of Sexually Transmitted Diseases
Urinary Tract Infections
Incidence and Prevalence of Urinary Tract Infections
Treatment of Urinary Tract Infections
Genitourinary Therapeutics in Development
Emerging Cancer Therapeutics
Experimental Vaccine Approaches
Antisense Nucleic Acids
Chemoprotectants
Gene Therapy
Oncogenes and Tumor Suppressor Genes
Photodynamic Therapy Compounds
Emerging Therapeutics for Erectile Dysfunction
Emerging STD Therapeutics
Emerging UTI Vaccine
Issues and Trends
Mergers and Acquisitions
Managed Care
Reimbursement
Aging Population
Direct-to-Customer Marketing
Market Size and Forecasts
Total Market
Benign Prostatic Hyperplasia
Genitourinary Cancers
Erectile Dysfunction
Incontinence
Sexually Transmitted Diseases
Urinary Tract Infections
Scope and Methodology
Chapter Two: Genitourinary Diseases And Disorders
Benign Prostatic Hyperplasia
Incidence and Prevalence
Signs and Symptoms
Treatment for Benign Prostatic Hyperplasia
PORT Guideline Recommendations
Diagnosis
Treatment
Pharmacological Intervention
Surgery
Alternatives to Incisional Surgery
Genitourinary Cancers
Bladder Cancer
Incidence, Prevalence, and Mortality
Causative Factors
Signs and Symptoms
Detecting Bladder Cancer
Treatment for Bladder Cancer
Cervical Cancer
Kidney and Renal Cancer
Incidence, Prevalence, and Mortality
Causative Factors
Signs of Kidney Cancer
Detecting Kidney Cancer
Treatment for Kidney and Renal Cancer
Ovarian Cancer
Incidence, Prevalence, and Mortality
Causative Factors
Signs of Ovarian Cancer
Detecting Ovarian Cancer
Treatment for Ovarian Cancer
Prostate Cancer
Incidence, Prevalence, and Mortality
Causative Factors
Signs of Prostate Cancer
Detecting Prostate Cancer
Treatment for Prostate Cancer
Erectile Dysfunction
Incidence and Prevalence
Causative Factors
Treatment for Erectile Dysfunction
Incontinence
Incidence and Prevalence
Detecting Incontinence
Treatment for Incontinence
Sexually Transmitted Diseases
Incidence and Prevalence
Major Bacterial STDs
Chlamydia
Gonorrhea
Syphilis
Major Viral STDs
Genital Warts/Human Papillomavirus
Genital Herpes
Hepatitis B Virus
Urinary Tract Infections (UTIs)
Incidence and Prevalence
UTIs in Men
UTIs in Women
Catheter-Associated UTIs
Causative Factors
Signs of a UTI
Detecting a UTI
Treatment for UTIs
Antibiotics in UTI Prevention
Estradiol Cream in Postmenopausal Women
Chapter Three: Genitourinary Therapeutic Products
Therapeuctics indicated in Genitourinary diseases and disorders
Therapeutics Indicated in Benign Prostatic Hyperplasia
Alpha Blockers
Finasteride
Therapeutics Indicated in Genitourinary Cancers
Bladder Cancer
Cervical Cancer
Kidney and Renal Cancer
Ovarian Cancer
Prostate Cancer
Therapeutics Indicated in Erectile Dysfunction
Therapeutics Indicated in Incontinence
Drugs Used to Facilitate Storage of Urine in Bladder
Drugs Used to Facilitate Bladder Emptying
Therapeutics Indicated in Sexually Transmitted Diseases
Bacterial STDs
Viral STDs
Therapeutics Indicated in Urinary Tract Infections
Genitourinary Therapeutics in Development
Emerging Cancer Therapeutics
Anticancer Vaccines
Antisense Nucleic Acids
Chemoprotectants
Gene Therapy
Oncogenes and Tumor Suppressor Genes
Photodynamic Therapy Compounds
Emerging Erectile Dysfunction Therapeutics
Emerging Sexually Transmitted Disease Therapeutics
Emerging Vaccine Against Urinary Tract Infections
Chapter Four: Issues And Trends
Overview of Pharmaceutical Industry
Mergers and Acquisitions
Managed Care
Industry in Transition
Managed Care and Hospital Costs
Managed Care and Doctors
Impact of Managed Care on Genitourinary Diseases
Managed Care and Cancer Diagnosis
Reimbursement
Capitated Cancer Care
Issues and Trends in Genitourinary Diseases
Aging Population
Direct-to-Customer Marketing
Genitourinary Cancers
Cancer Epidemic?
Standards for Optimal Cancer Care
New Tool for Bladder Cancer Management
Geographical Trends in Prostate Cancer
North Carolina Epicenter of Prostate Cancer Deaths
Erectile Dysfunction
Intracavernous Injection
Nontherapeutic Treatment Options
Incontinence
Age
Embarrassment
Costs of Incontinence
New Incontinence Guidelines Emphasize Nonsurgical Treatment
Novel Incontinence Devices
Sexually Transmitted Diseases
STDs More Prevalent in Women
Prevalence of HPV in Cervical Cancer
STDs Linked to AIDS
Urinary Tract Infections
Trend Toward Patient-Managed UTIs
Antibiotic Prophylaxis
Chapter Five: The Market For Genitourinary Therapeutics
Factors Affecting Demand
Demographics
Cost Containment
Market Size and Forecast
Scope and Methodology
Overall Market Size and Forecast
Benign Prostatic Hyperplasia
Market Size and Forecast
Leading Products and Their Sales
Trends
Genitourinary Cancers
Market Size and Forecast
Leading Products and Their Sales
Trends
Erectile Dysfunction
Market Size and Forecast
Leading Product
Trends
Incontinence
Market Size and Forecast
Leading Products
Trends
Sexually Transmitted Diseases
Market Size and Forecast
Leading Products
Trends
Urinary Tract Infections
Market Size and Forecast
Leading Products and Their Sales
Trends
Chapter Six: Company Profiles
Industry Participants
Pharmaceutical Companies
Biotechnology Companies
Abbott Laboratories
History and Lines of Business
Corporate Analysis
Research and Development
Genitourinary Therapeutics
Corporate Strategies
Agouron Pharmaceuticals, Inc.
History and Lines of Business
Corporate Analysis
Research and Development
Genitourinary Therapeutics
AG-331 and AG-337
AG-394
Corporate Strategies
Bristol-Myers Squibb Co.
History and Lines of Business
Corporate Analysis
Research and Development
Genitourinary Therapeutics
Cancer Therapeutics
Genitourinary Anti-Infectives
Chiron, Inc.
History and Lines of Business
Corporate Analysis
Research and Development
Genitourinary Therapeutics
Corporate Strategies
Connaught Laboratories, Inc.
History and Lines of Business
Financial Information
Corporate Analysis
Genitourinary Therapeutics
Corporate Strategies
Genentech, Inc.
History and Lines of Business
Corporate Analysis
Research and Development
Genitourinary Therapeutics
Corporate Strategies
Glaxo Wellcome Plc
History and Lines of Business
Financial Information
Corporate Analysis
Research and Development
Genitourinary Products
Hoffmann-La Roche Inc.
History and Lines of Business
Financial Information
Corporate Analysis
Research and Development
Genitourinary Therapeutics
Immunex Corp.
History and Lines of Business
Financial Information
Corporate Analysis
Research and Development
Genitourinary Therapeutics
Isis Pharmaceuticals
History and Lines of Business
Financial Information
Corporate Analysis
Research and Development
Genitourinary Therapeutics
Corporate Strategies
Eli Lilly and Company, Inc.
History and Lines of Business
Corporate Analysis
Research and Development
Genitourinary Therapeutics
Merck & Company
History and Lines of Business
Financial Information
Corporate Analysis
Research and Development
Genitourinary Therapeutics
Corporate Strategies
Pfizer Inc.
History and Lines of Business
Corporate Analysis
Research and Development
Genitourinary Therapeutics
Pharmacia & John, Inc.
History and Lines of Business
Financial Information
Corporate Analysis
Research and Development
Genitourinary Therapeutics
Quadra Logic Technologies, Inc.
History and Lines of Business
Financial Information
Corporate Analysis
Research and Development
Photofrin
Bone Marrow Purging
Other PDT Applications
Corporate Strategies
Rhone-Poulenc Rorer, Inc.
History and Lines of Business
Corporate Analysis
Research and Development
Genitourinary Therapeutics
Schering-Plough Corp.
History and Lines of Business
Financial Information
Corporate Analysis
Research and Development
IL-4 and IL-10
IL-11 and M-CSF
Leucomax
Other Agents
Genitourinary Therapeutics
SmithKline Beecham
History and Lines of Business
Financial Information
Corporate Analysis
Research and Development
Genitourinary Therapeutics
U.S. Bioscience Inc.
History and Lines of Business
Corporate Analysis
Research and Development
Genitourinary Therapeutics
Vivus, Inc.
History and Lines of Business
Financial Information
Corporate Analysis
Research and Development
Wyeth-Ayerst
History and Lines of Business
Financial Information
Corporate Analysis
Genitourinary Therapeutics
Zeneca Inc.
History and Lines of Business
Financial Information
Corporate Analysis
Research and Development
Genitourinary Therapeutics
Appendix: Company Names And Addresses
AbstractA pill to treat impotency? Approximately 20 million U.S. men are plagued by erectile dysfunction. As the American population ages, impotency and urinary incontinence become a growing concern. Baby boomers, who refuse to suffer in silence, are driving the development of innovative pharmacological solutions to these age-related problems. Also, will biotechnology produce a treatment for genitourinary cancers? This Kalorama Information report explores these issues and more. The major companies competing for a share of the market are profiled.
Get Full Details About This Report >>
|
